Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Blood (2021) 138 (Supplement 1): 3601.

https://doi.org/10.1182/blood-2021-149483

Published: 2021

Journal Articles

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

Blood (2021) 138 (Supplement 1): 1477.

https://doi.org/10.1182/blood-2021-145483

Published: 2021

Journal Articles

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

Mariko Ishibashi, PhD, Ryosuke Kinoshita, MD, Koiti Inokuchi, MD PhD Prof., Hiroshi Handa, MD PhD, Makoto Sasaki, MD PhD, Norio Komatsu, MD PhD, Yoichi Imai, MD PhD, Norina Hiroike, MD PhD, Junji Tanaka, Sakae Tanosaki, MD PhD, Shigeki Ito, MD, PhD, Mika Sunakawa, MD, Toshio Asayama, MD, Yasuko Kuribayashi-hamada, MD, Rimpei Morita, MD PhD, Hideto Tamura, MD PhD

Blood (2019) 134 (Supplement_1): 4361.

https://doi.org/10.1182/blood-2019-124635

Published: 2019

Journal Articles

The Presence of Minimal Residual Disease, As Determined By Highly Sensitive Quantitation of NPM1 -Mutatation, Provided Powerful Prognostic Information in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 5097.

https://doi.org/10.1182/blood-2019-127725

Published: 2019

Journal Articles

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD PhD, Kaichi Nishiwaki, MD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, MD PhD, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof., Junichi Sakamoto,, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof.

Blood (2019) 134 (Supplement_1): 4154.

https://doi.org/10.1182/blood-2019-130504

Published: 2019

Journal Articles

Upregulation of PD-L1 on Myeloma Cells By Immunomodulatory Agents Potentiates the Effect of Durvalumab

Mariko Ishibashi, PhD, Junichi Yamamoto, PhD, Takumi Ito, PhD, Hiroshi Handa, MD PhD, Koiti Inokuchi, MD PhD, Hidemi Takahashi, MD PhD, Hideto Tamura, MD PhD

Blood (2018) 132 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2018-99-112322

Published: 2018

Journal Articles

The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma

Mariko Ishibashi, PhD, Hideto Tamura, MD PhD, Toshio Asayama, MD, Yasuko Kuribayashi-hamada, MD, Asaka Onodera, MDPhD, Keiichi Moriya, MD PhD, Makoto Sasaki, MD PhD, Hiroshi Handa, MD PhDChief Division, Yoichi Imai, MDPhD, Norina Tanaka, MD, Junji Tanaka, MD PhD, Sakae Tanosaki, MDPhD, Shigeki Ito, MD PhD, Norio Komatsu, MD PhD, Koiti Inokuchi, MD PhD

Blood (2017) 130 (Supplement 1): 3055.

https://doi.org/10.1182/blood.V130.Suppl_1.3055.3055

Published: 2017

Journal Articles

The Prognostic Impact of KIT D816 Mutations in Core Binding Factor Acute Myeloid Leukemia

Blood (2016) 128 (22): 2785.

https://doi.org/10.1182/blood.V128.22.2785.2785

Published: 2016

Journal Articles

Amlexanox As a Possible Breakthrough Drug for MLL/AF4 -Positive Acute Lymphoblastic Leukemia

Hayato Tamai, MD PhD, Hiroki Yamaguchi, MD PhD, Koichi Miyake, MD PhD, Miyuki Takatori, Tomoaki Kitano, Syunsuke Yui, MD, Keiko Fukunaga, MD, Kazutaka Nakayama, MD PhD, Koiti Inokuchi, PhD MD

Blood (2016) 128 (22): 1590.

https://doi.org/10.1182/blood.V128.22.1590.1590

Published: 2016

Journal Articles

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

Chikashi Yoshida, MD PhD, Noriyoshi Iriyama, MDPhD, Yuho Najima, Shin Fujisawa, MD PhD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD, PhD, Shinichiro Okamoto, MD PhD, Kimihiro Kawakami, MDPhD, Naoki Takezako, MD PhD, Takashi Kumagai, MD PhD, Kazuma Ohyashiki, MD PhD, Jun Taguchi, MD PhD, Shingo Yano, MD PhD, Tadahiko Igarashi, MD, Yasuji Kouzai, MD PhD, Satoshi Morita, PhD Prof, Junichi Sakamoto, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof

Blood (2016) 128 (22): 1916.

https://doi.org/10.1182/blood.V128.22.1916.1916

Published: 2016

Journal Articles

The Clinical Features and Prognostic Impact of PRDM16 gene Expression in Adult Acute Myeloid Leukemia

Genki Yamato, MD, Hiroki Yamaguchi, MD PhD, Hiroshi Handa, MD PhD, Norio Shiba, MD PhD, Satoshi Wakita, Koiti Inokuchi, MD PhD Prof, Yusuke Hara, MD, Kentaro Ohki, MD PhD, Jun Okubo, MD PhD, Manabu Sotomatsu, MD, Hirokazu Arakawa, MD PhD, Yasuhide Hayashi, MD PhD

Blood (2016) 128 (22): 5228.

https://doi.org/10.1182/blood.V128.22.5228.5228

Published: 2016

Journal Articles

Analysis of Genetic Mutation of the Elderly Patients with Acute Myeloid Leukemia

Blood (2016) 128 (22): 5172.

https://doi.org/10.1182/blood.V128.22.5172.5172

Published: 2016

Journal Articles

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD, Kaichi Nishiwaki, MD PhD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof, Junichi Sakamoto, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof

Blood (2016) 128 (22): 791.

https://doi.org/10.1182/blood.V128.22.791.791

Published: 2016

Journal Articles

Clinical Significance and Pathopysiological Function of the Tim-3/Galection-9 Pathway in Myelodysplastic Syndromes

Toshio Asayama, MD, Mariko Ishibashi, PhD, Hideto Tamura, MD PhD, Yasuko Hamada, MD, Namiko Okuyama, MD, Asaka Onodera, MDPhD, Akiko Yamada, MD, Keiichi Moriya, MD PhD, Norio Yokose, MD PhD, Koiti Inokuchi, PhD MD

Blood (2015) 126 (23): 4117.

https://doi.org/10.1182/blood.V126.23.4117.4117

Published: 2015

Journal Articles

Profiling of somatic mutations in acute myeloid leukemia with FLT3 -ITD at diagnosis and relapse

Blood (2015) 126 (22): 2491–2501.

https://doi.org/10.1182/blood-2015-05-646240

Published: 2015

Includes: Supplemental data

Journal Articles

The Incidence of Pleural Effusion on Dasatinib Treatment Is Associated with CD56 Positive Cell Values One Month after Commencing Dasatinib and Achievement of an Early Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia Patients: Results of a D-First Study

Noriyoshi Iriyama, Shin Fujisawa, MD, Maki Hagihara, MDPhD, Chikashi Yoshida, MD PhD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD PhD, Shinichiro Okamoto, MD PhD, Kawakami Kimihiro, Naoki Takezako, MD PhD, Takashi Kumagai, MD PhD, Koiti Inokuchi, MD PhD, Kazuma Ohyashiki, Jun Taguchi, MD PhD, Shingo Yano, Tadahiko Igarashi, MD PhD, Yasuji Kouzai, MD PhD, Satoshi Morita, PhD, Junichi Sakamoto, MDPhD, Hisashi Sakamaki, MDPhD

Blood (2014) 124 (21): 3142.

https://doi.org/10.1182/blood.V124.21.3142.3142

Published: 2014

Journal Articles

Prospective Analysis of Cytomegalovirus Reactivation and the Immune State of Low-Grade B-Cell Lymphoma Patients Treated with Bendamustine

Noriko Isono, MD, Yoichi Imai, MD PhD, Chihiro Asano, MD, Michihiko Masuda, MD PhD, Shigeru Hoshino, MD PhD, Keiichi Moriya, MD PhD, Hideto Tamura, MD PhD, Koiti Inokuchi, MD PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD, Toshiko Motoji, MD PhD, Junji Tanaka, MD PhD

Blood (2014) 124 (21): 4411.

https://doi.org/10.1182/blood.V124.21.4411.4411

Published: 2014

Journal Articles

Clinical Utility of Slam Family Member CD229 in Identifying Tumor Cells and High-Risk Disease Markers, CD86 (B7-2) and CD126 (IL-6 receptor), Using Flow Cytometric Analysis in Multiple Myeloma

Akiko Yamada, MD, Hideto Tamura, MD PhD, Mariko Ishibashi, PhD, Koiti Inokuchi, MD PhD, Makoto Sasaki, MD PhD, Yuriko Yahata, MD, Norio Komatsu, MD PhD, Atsushi Isoda, MD PhD, Morio Matsumoto, Hiroshi Handa, MD PhD, Yoichi Imai, MD PhD, Junji Tanaka, MD PhD, Sakae Tanosaki, MD PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD, Michiaki Koike, MD PhD

Blood (2014) 124 (21): 2063.

https://doi.org/10.1182/blood.V124.21.2063.2063

Published: 2014

Journal Articles

Interaction Between B7-H1 Molecules on Myeloma Cells and PD-1 Molecules on T Cells Induces Resistance to Antimyeloma Chemotherapy

Blood (2014) 124 (21): 2018.

https://doi.org/10.1182/blood.V124.21.2018.2018

Published: 2014

Journal Articles

The D816V C-Kit Mutation Confers Higher Proliferation Activity By JAK-STAT and Src Family Kinase Pathways Compared to N822K C-Kit Mutation in Core-Binding Factor Acute Myeloid Leukemia

Ikuko Omori, MD, Hiroki Yamaguchi, MD PhD, Tomoaki Kitano, Noriko Miyake, PhD, Koichi Miyake, MD PhD, Koiti Inokuchi, PhD MD

Blood (2014) 124 (21): 2224.

https://doi.org/10.1182/blood.V124.21.2224.2224

Published: 2014

NARROW

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

The Presence of Minimal Residual Disease, As Determined By Highly Sensitive Quantitation of NPM1 -Mutatation, Provided Powerful Prognostic Information in Acute Myeloid Leukemia

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Upregulation of PD-L1 on Myeloma Cells By Immunomodulatory Agents Potentiates the Effect of Durvalumab

The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma

The Prognostic Impact of KIT D816 Mutations in Core Binding Factor Acute Myeloid Leukemia

Amlexanox As a Possible Breakthrough Drug for MLL/AF4 -Positive Acute Lymphoblastic Leukemia

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

The Clinical Features and Prognostic Impact of PRDM16 gene Expression in Adult Acute Myeloid Leukemia

Analysis of Genetic Mutation of the Elderly Patients with Acute Myeloid Leukemia

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

Clinical Significance and Pathopysiological Function of the Tim-3/Galection-9 Pathway in Myelodysplastic Syndromes

Profiling of somatic mutations in acute myeloid leukemia with FLT3 -ITD at diagnosis and relapse

The Incidence of Pleural Effusion on Dasatinib Treatment Is Associated with CD56 Positive Cell Values One Month after Commencing Dasatinib and Achievement of an Early Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia Patients: Results of a D-First Study

Prospective Analysis of Cytomegalovirus Reactivation and the Immune State of Low-Grade B-Cell Lymphoma Patients Treated with Bendamustine

Clinical Utility of Slam Family Member CD229 in Identifying Tumor Cells and High-Risk Disease Markers, CD86 (B7-2) and CD126 (IL-6 receptor), Using Flow Cytometric Analysis in Multiple Myeloma

Interaction Between B7-H1 Molecules on Myeloma Cells and PD-1 Molecules on T Cells Induces Resistance to Antimyeloma Chemotherapy

The D816V C-Kit Mutation Confers Higher Proliferation Activity By JAK-STAT and Src Family Kinase Pathways Compared to N822K C-Kit Mutation in Core-Binding Factor Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only